000020.Ks

The company maintains a relatively low price-to-book ratio of 0.44, indicating that the market values the company's equity at a discount to its book value. The price-to-tangible-book ratio is also 0.44, suggesting that intangible assets do not significantly influence the valuation. The enterprise value to EBITDA ratio is 367.08, which is notably high and may reflect either high expectations for future earnings or a lack of profitability in the current period.

Profitability metrics show a return on equity of 2.29% and a return on assets of 1.35%, both of which are below the typical thresholds for strong performance in the pharmaceutical industry. The company's operating income is significantly lower than its gross profit, indicating high operating expenses relative to revenue. The net income of 8,686,052,920 KRW is modest compared to the total revenue of 496,394,309,780 KRW, suggesting that the company is not efficiently converting revenue into profit.

The company's revenue is not segmented by geographic region or product line in the provided data, making it difficult to assess the concentration of revenue sources. However, the debt-to-equity ratio of 0.31 indicates a relatively conservative capital structure, with a manageable level of debt relative to equity. The current ratio of 1.07 suggests that the company has just enough current assets to cover its current liabilities, which may pose a liquidity risk if short-term obligations increase.

The company's free cash flow is negative at -34,817,434,560 KRW, indicating that it is spending more on capital expenditures than it is generating from operations. The operating cash flow of 15,698,716,580 KRW is positive but insufficient to cover the capital expenditures. This suggests that the company may need to rely on external financing or reduce capital spending to maintain liquidity.

The risk assessment indicates a medium liquidity risk and a low dilution risk. The company's net cash position is negative after subtracting total debt, which could affect its ability to meet short-term obligations. The low dilution risk suggests that the company is not likely to issue additional shares in the near term, which is a positive sign for existing shareholders.

Recent financial filings and transcripts do not provide specific details on new product launches, regulatory changes, or strategic partnerships. However, the company's financial performance and capital structure suggest that it may be facing challenges in maintaining profitability and liquidity. Investors should monitor the company's cash flow and debt levels closely to assess its financial health.